Opportunity ID: 275734

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-15-LCRP-CEA
Funding Opportunity Title: DoD Lung Cancer Clinical Exploration Award
Opportunity Category: Discretionary
Opportunity Category Explanation: CategoryExplanation
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 4
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 08, 2015
Last Updated Date:
Original Closing Date for Applications: Sep 16, 2015
Current Closing Date for Applications: Sep 16, 2015
Archive Date: Oct 16, 2015
Estimated Total Program Funding: $2,240,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The LCRP CEA mechanism was first offered in FY13. Since then, 35 CEA applications have been received, and 5 have been recommended for funding. This award mechanism supports early-phase, proof-of-principle clinical trials and correlative studies to investigate hypothesis-based, innovative interventions that have the potential to resolve current clinical barriers and result in a profound impact on the clinical management of lung cancer. While therapeutic approaches proposed for testing through the CEA must represent novel, hypothesis-based, “outside-the-box” approaches for treating lung cancer, they may include therapies already in clinical use, or undergoing clinical testing for other diseases, provided that the proposed use for lung cancer would lead to a major advancement for treating the disease. Outcomes from studies funded by this award are anticipated to provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform lung cancer clinical care. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.

Clinical Trials Category: The CEA supports clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drug or drug combinations, Class II or III devices, or other types of trials that conduct early clinical testing of innovative approaches for lung cancer. Information on clinical trials and phases/classes of study is provided in the “Human Subject Resource Document” available for download from eBRAP at https://ebrap.org/eBRAP/public/Program.htm.

Correlative Studies Category: The CEA-Correlative Studies category supports innovative, hypothesis-based, correlative studies that derive from ongoing or completed clinical trials supported by other funding sources. These correlative studies, if successful, will have the potential to significantly inform treatment strategies, identify subsets of patients for treatment with specific therapies, provide increased understanding of biological changes resulting from the intervention in lung cancer, or provide other insight that will significantly enhance clinical management of lung cancer. Examples of correlative studies appropriate for submission to the CEA-Correlative Studies category may include, but are not limited to:
• Analysis of biomarkers for prognosis and/or prediction or assessment of therapeutic response or progression
• Investigations of the mechanism of action or the development of resistance to a drug
• Analysis of immune response or factors associated with progression
• Characterization of tumor antigens for the development of new improved therapies

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Phone: (301) 682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 275734 Full Announcement-1 -> fy15 ind documentation form.pdf

Folder 275734 Full Announcement-1 -> lcrp_fy15_cea pa_gg.pdf

Packages

Agency Contact Information: Phone: (301) 682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00216042 Apr 08, 2015 Sep 16, 2015 View

Package 1

Mandatory forms

275734 RR_SF424_2_0-2.0.pdf

275734 RR_Budget_1_3-1.3.pdf

275734 RR_KeyPersonExpanded_2_0-2.0.pdf

275734 PerformanceSite_2_0-2.0.pdf

Optional forms

275734 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-09T11:17:51-05:00

Share This Post, Choose Your Platform!

About the Author: